Loading...
XNASXRTX
Market cap3mUSD
Dec 23, Last price  
1.12USD
1D
2.75%
1Q
-31.71%
IPO
-88.45%
Name

XORTX Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:XRTX chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
27.64%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
-36,922-414,834-474,201-3,775,923-629,576-1,284,602000
CFO
-7m
-106,803-107,78491,174-1,555,357-249,580-728,40100-6,583,165
Dividend
Jan 31, 20140.0001 USD/sh
Earnings
Mar 31, 2025

Profile

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
IPO date
Sep 30, 2015
Employees
3
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑02
Income
Revenues
Cost of revenue
8,785
2,254
Unusual Expense (Income)
NOPBT
(8,785)
(2,254)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(8,785)
(2,254)
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
5,051
17,881
BB yield
Debt
Debt current
12
66
Long-term debt
12
89
Deferred revenue
Other long-term liabilities
531
3,847
Net debt
(3,400)
(10,253)
(14,785)
Cash flow
Cash from operating activities
(6,583)
CAPEX
Cash from investing activities
(46)
Cash from financing activities
(361)
4,738
19,181
FCF
(294)
(8,877)
(1,403)
Balance
Cash
3,423
10,408
14,785
Long term investments
Excess cash
3,423
10,408
14,785
Stockholders' equity
(1,199)
23,536
22,132
Invested Capital
6,384
491
(1,658)
ROIC
1,506.10%
787.03%
ROCE
EV
Common stock shares outstanding
1,982
1,480
1,094
Price
Market cap
EV
EBITDA
105
(8,729)
(2,240)
EV/EBITDA
Interest
Interest/NOPBT